Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

ACR-368 Program Updates - Acrivon Therapeutics reported an overall response rate (ORR) of 39% in Arm 1 of the Phase 2b trial for endometrial cancer, with a higher ORR of 44% in subjects with over two prior lines of therapy [2] - The trial will now focus Arm 3 exclusively on subjects with serous endometrial cancer and two or fewer prior treatments due to higher response rates observed in this subgroup [2] - A confirmed ORR of 67% was noted in 12 subjects with serous endometrial cancer who had brain metastases (BM+), while the overall ORR for serous subjects was 52% compared to 22% for non-serous subjects [3] ACR-2316 Phase 1 Study Updates - The ongoing Phase 1 monotherapy dose-escalation study has dosed 33 patients with two weekly oral dosing schedules, establishing regimens of 160 mg QD on a 3d on / 4d off and 240 mg QD 2d on / 5d off [4] - A new cohort has been initiated to explore a bi-weekly 2d on / 12d off dosing regimen, aiming for enhanced single-agent activity and flexibility for future combination studies [5] - Clinical activity was observed at dose levels of 120 mg and above, with tumor shrinkage reported in 9 out of 20 evaluable patients with small cell lung cancer and squamous non-small cell lung cancer [5] Financial and Development Updates - Acrivon nominated ACR-6840 as the next preclinical development candidate, which is a potential first-in-class oral CDK11 inhibitor, with an IND submission anticipated in Q4 2026 [6] - As of December 31, 2025, the company reported preliminary cash and investments of approximately $119 million, expected to fund operations into Q2 2027 [6] Stock Performance - Acrivon Therapeutics shares experienced a decline of 28.81%, trading at $2.10 at the time of publication [7]